Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Jun 10, 2016
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma

SOUTH SAN FRANCISCO, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of gli...

May 24, 2016
OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology

Study met primary endpoint of improvement in progression free survival Preliminary data show improvement in overall survival of 2.6 months SOUTH SAN FRANCISCO, Calif., May 24, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology ind...

May 9, 2016
OXiGENE Reports First Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today reported financial results for the first quarter of 2016. For the three months ended March 31, 2016, OXiGENE reported a n...

Mar 30, 2016
Oxigene Receives Fast Track Designation From U.S. FDA for CA4P

SOUTH SAN FRANCISCO, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CA4P for the treatment of platinum-resistant ovari...

Mar 28, 2016
OXiGENE Reports 2015 Financial Results

SOUTH SAN FRANCISCO, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for 2015. For the year ended December 31, 2015, OXiGENE reported a net loss of $13.7 million compared to a net loss...

Mar 25, 2016
OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors

SOUTH SAN FRANCISCO, Calif., March 25, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to CA4P for the treatment of gastro-entero-pancreatic neuroendocrine tum...

Mar 24, 2016
OXiGENE Appoints Dr. Simon Pedder to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that Simon C. Pedder, Ph.D. has been appointed to OXiGENE's board of directors, effective March 21, 2016. "I am extremely pleased ...

Feb 3, 2016
OXiGENE Announces Upcoming Presentation at the BIO-CEO Conference and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced it will present a company overview on February 8, 2016 at 11:30 a.m. Eastern time at the 2016 BIO CEO & Investor Forum. ...

Jan 6, 2016
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors. T...

Dec 17, 2015
OXiGENE Receives European Orphan Drug Designation for OXi4503 to Treat Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to OXi4503 for the treatment of acute myeloid leukemia (AML). The designa...

FirstPrevious
3
...
NextLast
= add release to Briefcase